Raymond James Financial restated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research note published on Tuesday morning.

TGTX has been the topic of several other research reports. HC Wainwright restated a buy rating and issued a $33.00 price target on shares of TG Therapeutics in a report on Monday, December 11th. B. Riley began coverage on shares of TG Therapeutics in a research report on Friday, December 1st. They issued a buy rating and a $21.50 price objective for the company. SunTrust Banks reaffirmed a buy rating and issued a $28.00 price objective on shares of TG Therapeutics in a research report on Tuesday, October 3rd. BidaskClub raised shares of TG Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 24th. Finally, ValuEngine downgraded shares of TG Therapeutics from a hold rating to a sell rating in a research report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. TG Therapeutics has a consensus rating of Buy and an average target price of $25.50.

Shares of TG Therapeutics (TGTX) remained flat at $$8.25 during mid-day trading on Tuesday. The stock had a trading volume of 1,518,775 shares, compared to its average volume of 1,230,000. TG Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. analysts expect that TG Therapeutics will post -1.86 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Teachers Advisors LLC lifted its stake in TG Therapeutics by 7.1% during the first quarter. Teachers Advisors LLC now owns 75,432 shares of the biopharmaceutical company’s stock worth $879,000 after purchasing an additional 5,000 shares during the last quarter. Legal & General Group Plc lifted its stake in TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 384 shares during the last quarter. Vanguard Group Inc. lifted its stake in TG Therapeutics by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,790,583 shares of the biopharmaceutical company’s stock valued at $20,860,000 after buying an additional 246,404 shares during the last quarter. Geode Capital Management LLC lifted its stake in TG Therapeutics by 24.3% in the first quarter. Geode Capital Management LLC now owns 362,353 shares of the biopharmaceutical company’s stock valued at $4,221,000 after buying an additional 70,751 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 1,395 shares during the last quarter. 50.45% of the stock is owned by institutional investors and hedge funds.

WARNING: “TG Therapeutics (TGTX) Given Buy Rating at Raymond James Financial” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/tg-therapeutics-tgtx-given-buy-rating-at-raymond-james-financial/1768200.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.